Evolus, Inc. (EOLS)
NASDAQ:EOLS
Want to see EOLS full AI Analyst Report?
EOLS Stock Chart & Stats
$4.69
-$0.47(-4.38%)
At close: 4:00 PM EST
$4.69
-$0.47(-4.38%)
Day’s Range― - ―
52-Week Range$3.86 - $10.62
Previous CloseN/A
Volume344.54K
Average Volume (3M)897.65K
Market Cap
$406.32M
Enterprise Value$547.12M
Total Cash (Recent Filing)$49.79M
Total Debt (Recent Filing)$164.90M
Price to Earnings (P/E)―
Beta0.88
Next Earnings
Aug 05, 2026EPS Estimate
-0.04Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.67
Shares Outstanding65,854,750
10 Day Avg. Volume717,774
30 Day Avg. Volume897,648
Financial Highlights & Ratios
PEG Ratio6.72
Price to Book (P/B)-18.55
Price to Sales (P/S)1.44
P/FCF Ratio-9.38
Enterprise Value/Market Cap1.35
Enterprise Value/Revenue1.81
Enterprise Value/Gross Profit2.77
Enterprise Value/Ebitda-38.99
Forecast
1Y Price Target
$14.50Price Target Upside209.17% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-0.09
Revenue Forecast (FY)$330.50M
Bulls Say, Bears Say
Bulls Say
Revenue GrowthSustained top-line momentum (TTM revenue up ~155% and multi-year expansion) indicates durable demand for Jeuveau and growing product mix. Consistent revenue growth improves fixed-cost absorption potential and supports a pathway to operating leverage as commercial scale increases.
Gross MarginsHigh adjusted gross margins (~68%) reflect favorable product economics and pricing power for injectable treatments. Durable margin structure supports long-term profitability improvement as scale grows and shields operating profits from modest cost inflation or competitive pricing pressure.
Commercial Reach & LoyaltyA large and growing loyalty ecosystem, expanding account base and high reorder rates create recurring demand and predictable unit flows. Embedding AI in the data platform and a direct sales model strengthen long-term practitioner engagement and repeat patient pull-through.
Bears Say
Balance Sheet LeverageNegative equity and elevated debt levels reduce financial flexibility and raise refinancing and covenant risk. A levered balance sheet constrains investment optionality, increases financing costs over time, and makes the company more sensitive to adverse industry or capital-market shifts.
Negative Cash FlowPersistent negative operating and free cash flow force reliance on external capital to fund operations and growth. Continued cash burn elevates liquidity and dilution risk if capital access tightens, limiting ability to self‑fund marketing, launches, or international expansion long term.
Product & Competitive RisksFillers remain a challenged category for Evolus with Evolisse contribution still small and incumbents entrenched. Future growth relies on successful Sculp and Esteem launches; entrenched competition and sampling dynamics could require sustained investment to protect share and margins.
Evolus News
EOLS FAQ
What was Evolus, Inc.’s price range in the past 12 months?
Evolus, Inc. lowest stock price was $3.86 and its highest was $10.62 in the past 12 months.
What is Evolus, Inc.’s market cap?
Evolus, Inc.’s market cap is $406.32M.
When is Evolus, Inc.’s upcoming earnings report date?
Evolus, Inc.’s upcoming earnings report date is Aug 05, 2026 which is in 61 days.
How were Evolus, Inc.’s earnings last quarter?
Evolus, Inc. released its earnings results on May 04, 2026. The company reported -$0.046 earnings per share for the quarter, beating the consensus estimate of -$0.113 by $0.067.
Is Evolus, Inc. overvalued?
According to Wall Street analysts Evolus, Inc.’s price is currently Undervalued.
Does Evolus, Inc. pay dividends?
Evolus, Inc. does not currently pay dividends.
What is Evolus, Inc.’s EPS estimate?
Evolus, Inc.’s EPS estimate is -0.04.
How many shares outstanding does Evolus, Inc. have?
Evolus, Inc. has 65,854,750 shares outstanding.
What happened to Evolus, Inc.’s price movement after its last earnings report?
Evolus, Inc. reported an EPS of -$0.046 in its last earnings report, beating expectations of -$0.113. Following the earnings report the stock price went up 14.158%.
Which hedge fund is a major shareholder of Evolus, Inc.?
Currently, no hedge funds are holding shares in EOLS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Evolus Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$14.50 (209.17% Upside)
$14.50 (209.17% Upside)
Blogger Sentiment
Bullish
EOLS Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 1.3M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.3%
Last 30 Days ▼ 5.9%
Last 30 Days ▼ 5.9%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-39.45%
12-Months-Change
Fundamentals
Return on Equity
174.92%
Trailing 12-Months
Asset Growth
3.41%
Trailing 12-Months
Company Description
Evolus, Inc.
Evolus, Inc., a performance beauty company, provides medical aesthetic products for physicians and their patients in the United States. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. The company was incorporated in 2012 and is headquartered in Newport Beach, California.
EOLS Company Deck
EOLS Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented a broadly constructive picture: revenue growth (Q1 +7%), healthy margins (adjusted gross margin 68%), expanding commercial footprint and loyalty (Rewards members +27% YoY), and a return to positive adjusted EBITDA ($0.6M) alongside reiterated full-year guidance and planned product launches (Esteem in Europe, Sculp FDA in Q4). Key risks include timing/seasonality comparatives, a newly announced 15% South Korea tariff on certain products, a still-small contribution from Evolisse amid a soft filler market, and continued competitive entrants. On balance, the operational improvements, profitability momentum, and clear pipeline/launch cadence outweigh the cited headwinds.View all EOLS earnings summariesEOLS Stock 12 Month Forecast
Average Price Target
$14.50
▲(209.17% Upside)
Technical Analysis
Emergent Biosolutions
―
Rockwell Med
―
Organogenesis Holdings
―
Aquestive Therapeutics
―
Journey Medical Corp
―
Ownership Overview
3.13% Insiders
8.01% Mutual Funds
40.27% Other Institutional Investors
37.98% Public Companies and
Individual Investors